I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context of the COVID-19 pandemic. This schedule was approved in Europe based on modeling/simulation (https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.3062), but the FDA rejected the every 6 week dosing in February 2020.